Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12 - 15 January 2026

Human medicines European public assessment report (EPAR): Entecavir Viatris (previously Entecavir Mylan), entecavir, Date of authorisation: 18/09/2017, Revision: 11, Status: Authorised

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 June 2025, 15:00 (CEST) to 12 June 2025, 17:30 (CEST)

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 June 2024, 15:00 (CEST) to 18 June 2024, 17:30 (CEST)

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 July 2023, 15:00 (CEST) to 20 July 2023, 17:00 (CEST)

Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals Under evaluation, 16/01/2026

Briefing Document for Quality Innovation Group (QIG) 1-to-1 meeting

Webinar on the use of platform technologies in the non-clinical and clinical domains, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 March 2026, 09:25 (CET) to 2 March 2026, 12:15 (CET)

Paediatric Committee (PDCO): 11-14 November 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 November 2025 to 14 November 2025

Minutes - PDCO minutes of the 11-14 November 2025 meeting